The great debate: stopping immunomodulators and biologics in Crohn’s disease patients in remission

Jana G Hashash Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, 200 Lothrop Street - PUH, M2, C Wing, Pittsburgh, PA 15213, USA

Miguel D Regueiro University of Pittsburgh School of Medicine, Associate Chief for Education and Inflammatory Bowel Disease Center, Division of Gastroenterology, Hepatology and Nutrition, Mezzanine Level, C-Wing, 200 Lothrop Street, Pittsburgh, PA 15213, USA. [email protected]

References

Camus M, Seksik P, Bourrier A et al. Long-term outcome of patients with Crohn’s disease who respond to azathioprine. Clin. Gastroenterol. Hepatol. 11(4), 389–394 (2013).
PubMed Web of Science ®Google Scholar
Louis E, Mary JY, Vernier-Massouille G et al.; Groupe D’etudes Thérapeutiques Des Affections Inflammatoires Digestives. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142(1), 63–70.e5; quiz e31 (2012).
PubMed Web of Science ®Google Scholar
Molnár T, Lakatos PL, Farkas K et al. Predictors of relapse in patients with Crohn’s disease in remission after 1 year of biological therapy. Aliment. Pharmacol. Ther. 37(2), 225–233 (2013).
PubMed Web of Science ®Google Scholar
Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn’s disease treated with combination therapy. Am. J. Gastroenterol. 105(5), 1142–1149 (2010).
PubMed Web of Science ®Google Scholar
Van Assche G, Magdelaine-Beuzelin C, D’Haens G et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134(7), 1861–1868 (2008).
PubMed Web of Science ®Google Scholar
Waugh AW, Garg S, Matic K et al. Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment. Pharmacol. Ther. 32(9), 1129–1134 (2010).
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The great debate: stopping immunomodulators and biologics in Crohn’s disease patients in remission

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The great debate: stopping immunomodulators and biologics in Crohn’s disease patients in remission

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date